Abstracts tagged "biologic drugs and rheumatoid arthritis (RA)"

Abstract Number: 532 • 2019 ACR/ARP Annual Meeting
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Hayato Hisaki ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: L08 • 2018 ACR/ARHP Annual Meeting
High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
Anita Boyapati¹, Jérôme Msihid², Sergio Schwartzman³, Ernest Choy⁴, Mark C. Genovese⁵, Gerd R. Burmester⁶, Gordon Lam⁷, Toshio Kimura¹, Jonathan Sadeh⁸ and Neil M.H. Graham¹, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi Chilly-Mazarin, Chilly-Mazarin, NJ, France, ³Hospital for Special Surgery, New York, NY, ⁴CREATE Center, Cardiff University School of Medicine, Cardiff, Great Britain, ⁵Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ⁶Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ⁷Atrium Health, Charlotte, NC, ⁸Sanofi, Bridgewater, NJ
Background/Purpose: Clinical application of biomarkers to predict response to therapy is the next frontier in RA. Despite the key role of IL-6 in RA, the…
Abstract Number: 625 • 2018 ACR/ARHP Annual Meeting
Tapering of Biological Antirheumatic Drugs in Rheumatoid Arthritis Patients Is Achievable and Cost Effective in Daily Clinical Practice: DATA from the Brussels UCL RA Cohort
Stéphanie Dierckx¹, Bernard R. Lauwerys², Tatiana Sokolova¹, Laurent Meric de Bellefon¹, Maria Stoenoiu¹, Adrien Nzeusseu Toukap³, Frédéric A. Houssiau², Aleksandra Avramovska¹ and Patrick Durez¹, ¹Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Several studies have demonstrated that Rheumatoid Arthritis (RA) patients achieving low disease activity or remission are able to taper biological disease-modifying antirheumatic drugs (bDMARDs).…
Abstract Number: 1016 • 2017 ACR/ARHP Annual Meeting
The Genetic Biomarkers to Predicting Response of TNF Inhibitors Treatment in Rheumatoid Arthritis
So-Young Bang¹, Youngho Park², Kwangwoo Kim³, Young Bin Joo⁴, Soo-Kyung Cho⁵, Chan-Bum Choi¹, Yoon-Kyoung Sung², Tae-Hwan Kim², Jae-Bum Jun¹, Dae-Hyun Yoo¹, Hye-Soon Lee⁶ and Sang-Cheol Bae⁷, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³4Department of Biology, Kyung Hee University, Seoul, Korea, Republic of (South), ⁴Internal Medicine, Department of Rheumatology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Gyeonggido, Korea, Republic of (South), ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁶Hanyang University Guri Hospital, Gyeonggi-do, Korea, Republic of (South), ⁷Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Although pharmacogenetic studies of TNF inhibitors (TNFi) response presented the estimates of high heritability, only few loci with suggestive weak association as biomarkers for…
Abstract Number: 2242 • 2016 ACR/ARHP Annual Meeting
Comparison of Assessment and Management of RA and Other Rheumatic Diseases By Rheumatologists in Private Practices or an Academic Medical Center
Anna Coleman¹, Herbert Lindsley² and Jo Wick³, ¹Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Internal Medicine, University of Kansas Medical Center, Kansas City, KS, ³Biostatistics, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Since 80% of rheumatologists practice outside the university setting, training projects for rheumatoid arthritis (RA) may benefit from an improved understanding of RA management…
Abstract Number: 2630 • 2016 ACR/ARHP Annual Meeting
EBV Load Quantification in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis Treated By Abatacept and Tocilizumab
Emmanuel Massy¹, Gaétan Texier², Olivier Muis Pistor³, marielle Martin⁴, Isabelle Auger⁵, jean-Pierre Mattei⁶, Sandrine Guis⁷, Thao Pham^8,9,10, Jean Roudier^11,12,13 and Nathalie Balandraud¹⁴, ¹Rheumatology, Hôpital Sainte Marguerite, marseille, France, ²Centre d'épidémiologie et de santé publique des armées (CESPA) Marseille, marseille, France, ³rheumatology, Hôpital Sainte marguerite, marseille, France, ⁴INSERM UMRS 1097, marseille, France, ⁵Université Aix Marseille II, INSERM UMR1097, Marseille, France, ⁶Rheumatology, Hôpital Sainte Marguerite AP-HM, marseille, France, ⁷Rheumatology 1, CRMBM-CEMEREM 7339, Aix-Marseille Université, AP-HM, CNRS, Marseilles, France, ⁸Rheumatology, Service de rhumatoiogie, Marseille, France, ⁹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ¹⁰Rheumatology, APHM, Aix Marseille University, Marseille, France, ¹¹Laboratoire d'Immunogénétique de la polyarthrite rhumatoide, INSERM UMR639, Marseille Cedex 09, France, ¹²Rheumatology 1, Aix Marseille Univ, AP-HM, INSERM, Marseille, France, ¹³Hopital Sainte Marguerite, Marseille, France, ¹⁴Rheumatology 1, AP-HM, INSERM, Marseilles, France
Background/Purpose: For twenty years, the Epstein-Barr Virus (EBV) has been suspected to contribute to Rheumatoid Arthritis (RA). Immunity against EBV is impaired in RA. RA…
Abstract Number: 2419 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review
Lynden Roberts^1,2, Kathleen Tymms³, Julien de Jager⁴, Geoffrey Littlejohn⁵, Hedley Griffiths⁶, David Nicholls⁷, Paul Bird⁸, Jennifer Young⁹ and Jane Zochling¹⁰, ¹JCU Clinical School, Townsville, QLD, Australia, ²Monash Medical Centre, Clayton, VIC, Australia, ³Canberra Rheumatology, Canberra, ACT, Australia, ⁴Olser House, Southport, QLD, Australia, ⁵Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia, ⁶Barwon Rheumatology Service, Geelong, VIC, Australia, ⁷Coast Joint Care, Maroochydore, QLD, Australia, ⁸Combined Rheumatology Practice, Sydney, NSW, Australia, ⁹4-10 Inman Road, Roche Products Pty Limited, Sydney, NSW, Australia, ¹⁰Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia
Background/Purpose: In the last decade, biologic medications have transformed the management of RA. The effectiveness of these medications has been reported in numerous randomized controlled…
Abstract Number: 1910 • 2014 ACR/ARHP Annual Meeting
Risk of Hypersensitiviy Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics
Huifeng Yun¹, Fenglong Xie², Lang Chen³, James Lewis⁴ and Jeffrey R. Curtis⁵, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Healthcare providers have been alerted to the potential drug hypersensitivity reactions (HSRs, an adverse drug reaction that are uncommon but may be severe and…
Abstract Number: 1541 • 2014 ACR/ARHP Annual Meeting
Distinct Regulation of T Helper Cell Differentiation By Biologic DMARD Therapy in Rheumatoid Arthritis
Shingo Nakayamada¹, Satoshi Kubo¹, Maiko Yoshikawa¹, Naoki Yunoue¹, Yusuke Miyazaki¹, Kazuyoshi Saito¹ and Yoshiya Tanaka², ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), T helper cells can differentiate into functionally distinct subsets, leading to the persistent inflammation and immune abnormality…
Abstract Number: 2823 • 2014 ACR/ARHP Annual Meeting
Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Roy Fleischmann^1,2, Dennis L. Decktor³, Chunpeng Fan⁴, Hubert Van Hoogstraten⁵ and Mark C Genovese⁶, ¹Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Biostatistics, Sanofi, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose For patients with prior exposure to tumor necrosis factor-α inhibitor (TNF-I), the likelihood of response to subsequent treatment with a TNF-I declines with the…
Abstract Number: 2528 • 2014 ACR/ARHP Annual Meeting
Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis
Yusuf Yazici¹, Chunqiao Luo² and Christopher Swearingen³, ¹New York University Hospital for Joint Diseases, New York, NY, ²University of Arkansas, Biostatistics, Little Rock, AR, ³Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose NNT analysis is a useful tool for putting RCT efficacy results into perspective in patient care. For clinical decision making, the NNT is a…
Abstract Number: 1478 • 2013 ACR/ARHP Annual Meeting
The Prevalence Of Biological Monotherapy Among Rheumatoid Arthritis Patients In Denmark: Results From The Danish Nationwide Danbio Registry
Tanja Schjoedt Joergensen¹, Lars-Erik Kristensen², Tove Lorenzen³, Jørgen Jensen⁴, Lida Zanjani⁵, Toke Laursen⁶, Sheraz Butt⁷, Mette Y. Dam⁸, Hanne M. Lindegaard⁹, Jakob Espesen¹⁰, Oliver Hendricks¹¹, Prabhat Kumar¹², Anita Kincses¹³, Line H. Larsen¹⁴, Marlene Andersen¹⁵, Esben K. Næser¹⁶, Dorte V. Jensen¹⁷, Jolanta Grydehøj¹⁸, Barbara Unger¹⁹, Ninna Dufour²⁰, Vibeke N. Sørensen²¹, Sara Vildhøj²², Inger Marie J. Hansen²³, Johnny Raun²⁴ and Merete Lund Hetland²⁵, ¹The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ²Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden, ³Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁴Department of Rheumatology, Køge, Denmark, ⁵Department of Rheumatology, Glostrup, Denmark, ⁶Department of Rheumatology, Gentofte, Denmark, ⁷Department of Rheumatology, Frederiksberg, Denmark, ⁸Department of Rheumatology, Aarhus, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁰Department of Rheumatology, Vejle, Denmark, ¹¹Department of Rheumatology, Gråsten, Denmark, ¹²Department of Rheumatology, Esbjerg, Denmark, ¹³Department of Rheumatology, Copenhagen, Denmark, ¹⁴Department of Rheumatology, Aalborg, Denmark, ¹⁵Department of Rheumatology, Aalborg University, Hjørring, Denmark, ¹⁶Department of Rheumatology, Silkeborg, Denmark, ¹⁷Department of Rheumatology, Rønne, Denmark, ¹⁸Department of Rheumatology, Viborg, Denmark, ¹⁹Department of Rheumatology, Horsens, Denmark, ²⁰Department of Rheumatology, Helsingør, Denmark, ²¹Department of Rheumatology, Randers, Denmark, ²²Department of Rheumatology, Holstebro, Denmark, ²³Department of Rheumatology, Svendborg, Denmark, ²⁴Department of Rheumatology, Fredericia, Denmark, ²⁵Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: It is estimated that between 10 and 30% of rheumatoid arthritis (RA) patients are methotrexate (MTX)-intolerant and discontinuation is common in clinical practice. For…
Abstract Number: 1442 • 2013 ACR/ARHP Annual Meeting
Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry
HCB Leffers^1,2, Mikkel Østergaard³, Bente Glintborg⁴, Niels Steen Krogh⁵, Ulrik Tarp⁶, Tove Lorenzen⁷, Annette Hansen⁸, Lene Dreyer⁹ and Merete L. Hetland³, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frderiksberg, Denmark, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁸Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark
Background/Purpose: Treatment with abatacept and tocilizumab has been shown to be efficacious in rheumatoid arthritis (RA) patients refractory to tumor necrosis factor inhibitor (TNFi). However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].